MK2140-011 A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) by Mary Beth Wilwerding | Sep 3, 2026
MK2140-003 A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) by Mary Beth Wilwerding | Aug 19, 2026
GO45434 Phase II, Open-Label, Multicenter Study To Evaluate The Optimization Of The Cytokine Release Syndrome Profile For Glofitamab In Combination With Gemcitabine Plus Oxaliplatin In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma by Mary Beth Wilwerding | Aug 19, 2026
